NEW YORK (GenomeWeb) – NanoString Technologies said after the close of the market Tuesday that Canadian regulatory authorities have cleared the firm's Prosigna Breast Cancer Prognostic Gene Signature Assay for marketing.

The Class III Medical Device License from Health Canada clears the Prosigna assay for assessing a woman's 10-year risk of distant recurrence of breast cancer and accurately identifying the intrinsic biologic subtype of the tumor.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.